The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) facility at Wadki, Pune, following serious irregularities uncovered during inspections linked to the company's Reactin Plus tablets. The action, one of the most significant regulatory moves against a major pharmaceutical brand in recent months, stems from packaging violations, non-compliance with recall orders, and storage lapses.

What the Inspection Found

During a June 2025 inspection, FDA officials discovered unauthorised promotional text — specifically the words 'analgesic and antipyretic' — printed on the packaging of Reactin Plus, a Schedule H prescription medicine. Under Indian drug regulations, Schedule H medicines cannot be promoted or sold without a doctor's prescription, and any labelling that encourages self-medication is a direct violation of the Drugs and Cosmetics Act, 1940 and its accompanying Rules of 1945.

The regulator subsequently seized Reactin Plus stock valued at over ₹11 lakh and issued a market recall order. However, according to the FDA, the company failed to fully comply with the recall directions — a lapse that compounded the original offence.

Storage and Distribution Lapses

A follow-up inspection of Cipla's C&F operations at the Wadki facility revealed a broader pattern of non-compliance. Inspectors found discrepancies between physical and computerised stock records, gaps in purchase and sale documentation, and inadequate procedures for handling expired medicines.

Notably, medicines were found stored directly on the floor, with insufficient pallet and rack infrastructure — a basic Good Distribution Practice (GDP) violation that raises questions about inventory integrity across the supply chain. These findings suggest the irregularities were not isolated to packaging alone.

Regulatory Action and Show-Cause Process

The FDA issued a formal show-cause notice to the company before proceeding with cancellation, giving Cipla an opportunity to respond. After examining the company's reply, the regulator determined that the violations warranted licence cancellation under the relevant provisions of the Drugs and Cosmetics Act and Drugs Rules.

FDA Commissioner Tukaram Mundhe stated that the department would not extend any leniency on matters of drug safety and public health, particularly concerning the advertising, sale, storage, and distribution of Schedule H prescription medicines. 'Any violation of rules by any entity involved in the manufacture and distribution of medicines will invite strict action as per law,' he said.

Why This Matters for Drug Safety

The FDA's concern goes beyond paperwork. Unauthorised promotional language on a prescription painkiller and fever reducer could, according to the regulator, encourage consumers to self-medicate — bypassing physician oversight and increasing the risk of misuse or adverse reactions. This comes amid growing national attention to over-the-counter misuse of Schedule H drugs, a category that includes antibiotics, steroids, and analgesics.

This is not the first time Maharashtra's FDA has taken firm action against pharmaceutical distribution irregularities, but the cancellation of licences for a facility linked to a major listed company like Cipla signals that the regulator is prepared to act regardless of corporate scale. The pharmaceutical industry will be watching closely to see whether Cipla challenges the order or moves swiftly to restore compliance.